Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.
Thermo Fisher found that its blood tests could monitor the changing genetics of lung tumors and illustrate developments in drug resistance over time.
ArcherDX has closed on a $60 million financing round to support its companion diagnostic program spanning solid and blood tumors.
Grail’s multicancer blood test has taken a helpful step closer to approval, by obtaining a breakthrough device designation from the FDA.
Zebra Medical received an FDA go-ahead to use AI to quickly scour X-rays and alert clinicians for signs of pneumothorax.
AliveCor has secured an FDA clearance for its personal device offering six leads, providing more detailed views into heartbeats and arrhythmias.
Pulmonx has secured $65 million in new equity financing for its global commercialization efforts through a round led by Ally Bridge Group.
The cryoablation therapy will featuring an integrated, real-time guidance system for the treatment of atrial fibrillation.
Medtronic walked away from Responsive Orthopedics, which it bought three years ago to disrupt the knee replacement market with cheaper joints.
Medical device cybersecurity provider MedCrypt raised $5.3 million, with plans to expand its team with new sales and software engineering positions.
